Skip to main content
Industry News
Rare pediatric disease tag granted for GM1 gangliosidosis gene therapy

Passage Bio's gene therapy candidate PBGM01 was granted rare pediatric disease designation by the FDA as a treatment of infantile GM1 gangliosidosis. Passage BIO plans to launch a Phase I/II clinical trial in the fourth quarter for PBGM0.

Full Story: